Literature DB >> 17852927

Urinary tract infection due to Achromobacter xylosoxidans: report of 9 cases.

Daniel Tena1, Alejandro González-Praetorius, Mercedes Pérez-Balsalobre, Oliva Sancho, Julia Bisquert.   

Abstract

Urinary tract infection (UTI) due to Achromobacter xylosoxidans is rare. The aims were to know the frequency and clinical characteristics of this infection in our area. We performed a retrospective analysis of 9 patients with UTI caused by this organism diagnosed over a period of 13 y. The mean age was 63.1 y. All patients had underlying diseases or urological abnormalities. The most frequent underlying diseases were solid or hematological malignancies (3 cases). Seven patients (77.7%) had urological abnormalities. Eight patients had symptoms of cystitis and 1 remained asymptomatic. Seven patients had community acquired UTIs. Clinical outcome was favourable in 5 patients after antibiotic treatment and recurrence occurred in 3 patients who had urological abnormalities. All isolates were susceptible to imipenem and piperacillin-tazobactam, 88.8% were susceptible to ceftazidime and 77.7% were susceptible to trimethoprim-sulfamethoxazole. High frequencies of resistance to ampicillin (100%), amoxicillin/clavulanic acid (78%), cefuroxime (100%), cefotaxime (67%), norfloxacin (89%), ciprofloxacin (78%), nitrofurantoin (89%) and gentamicin (67%) were observed. UTI due to A. xylosoxidans was predominantly observed in elderly patients with predisposing factors, especially urological abnormalities, malignancies and immunosuppression. Treatment can be difficult due to the high level of antibiotic resistance. Trimethoprim-sulfamethoxazole may be useful for treatment, particularly in outpatients with community acquired infections.

Entities:  

Mesh:

Year:  2008        PMID: 17852927     DOI: 10.1080/00365540701558714

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  20 in total

1.  Genetic and biochemical characterization of a novel metallo-β-lactamase, TMB-1, from an Achromobacter xylosoxidans strain isolated in Tripoli, Libya.

Authors:  Allaaeddin El Salabi; Pardha Saradhi Borra; Mark A Toleman; Ørjan Samuelsen; Timothy R Walsh
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

2.  First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM.

Authors:  Julien Bador; Lucie Amoureux; Jean-Marie Duez; Anthony Drabowicz; Eliane Siebor; Catherine Llanes; Catherine Neuwirth
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

3.  Achromobacter xylosoxidans Cellular Pathology Is Correlated with Activation of a Type III Secretion System.

Authors:  Adam M Pickrum; Orlando DeLeon; Aaron Dirck; Maxx H Tessmer; Molly O Riegert; Julie A Biller; Nathan A Ledeboer; John R Kirby; Dara W Frank
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

4.  Achromobacter xylosoxidans infection presenting as a pulmonary nodule mimicking cancer.

Authors:  Stephanie L Claassen; Jason M Reese; Vincent Mysliwiec; Steven D Mahlen
Journal:  J Clin Microbiol       Date:  2011-05-18       Impact factor: 5.948

5.  Multilocus sequence analysis of isolates of Achromobacter from patients with cystic fibrosis reveals infecting species other than Achromobacter xylosoxidans.

Authors:  Winnie Ridderberg; Mikala Wang; Niels Nørskov-Lauritsen
Journal:  J Clin Microbiol       Date:  2012-06-06       Impact factor: 5.948

6.  Got black swimming dots in your cell culture? Identification of Achromobacter as a novel cell culture contaminant.

Authors:  Jennifer Sue Gray; Janette Marie Birmingham; Jenifer Imig Fenton
Journal:  Biologicals       Date:  2009-11-18       Impact factor: 1.856

7.  Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates.

Authors:  Lucie Amoureux; Julien Bador; Sakina Fardeheb; Cédric Mabille; Charlyne Couchot; Clémence Massip; Anne-Lise Salignon; Guillaume Berlie; Véronique Varin; Catherine Neuwirth
Journal:  Appl Environ Microbiol       Date:  2013-09-13       Impact factor: 4.792

Review 8.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

9.  Achromobacter species endocarditis: A case report and literature review.

Authors:  Catherine Derber; Kara Elam; Betty A Forbes; Gonzalo Bearman
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

10.  Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump.

Authors:  Julien Bador; Lucie Amoureux; Emmanuel Blanc; Catherine Neuwirth
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.